anti-CD19 CAR T cell therapy

BIOLOGICAL3 trials

Sponsors

Miltenyi Biomedicine GmbH, Kara Yakhteh Tajhiz Azma Company, Peking University Third Hospital

Conditions

ANCA Associated Vasculitis (AAV)Antiphospholipid SyndromeDermatomyositisInflammatory MyopathiesPolymyositisRelapse/Refractory B-cell Acute Lymphoblastic LeukemiaSjogren SyndromeSystemic Lupus Erthematosus

Phase 1

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease

RecruitingNCT06347718

Miltenyi Biomedicine GmbHDermatomyositis, Polymyositis, Systemic Lupus Erythematosus +1

Start: 2023-07-17End: 2026-05-31Target: 24Updated: 2025-09-30

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

RecruitingNCT06635330

Kara Yakhteh Tajhiz Azma CompanyRelapse/Refractory B-cell Acute Lymphoblastic Leukemia

Start: 2024-05-20End: 2027-09-22Target: 5Updated: 2024-10-10

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

RecruitingNCT06828042

Peking University Third HospitalANCA Associated Vasculitis (AAV), Antiphospholipid Syndrome, Inflammatory Myopathies +3

Start: 2025-07-01End: 2027-12-31Target: 9Updated: 2025-08-20

Related Papers

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.

2026-01-07